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ABSTRACT 
LESENDE, VIVIAN A., M.S., December 2015, Biological Sciences 
RNA Expression of Receptors for Growth Hormone, Insulin-like Growth Factor 1, and 
Insulin in Mouse Whole Adipose Tissue, Stromal Vascular Fraction, and Adipocytes 
Director of Thesis: Darlene E. Berryman 
Increasing rates of obesity and associated complications worldwide have 
increased research interest in the complex interplay of hormones, metabolism, and 
adiposity. There is much evidence indicating that hormones such as growth hormone 
(GH), insulin-like growth factor 1 (IGF-1), and insulin affect white adipose tissue (WAT) 
in a depot-specific manner. This suggests that hormone-induced intracellular signaling is 
more active in some WAT depots compared to others, as evidenced by hormone receptor 
expression levels. To add another layer of complexity, WAT is made up of many cell 
types with distinct functions, including adipocytes and cells of the stromal vascular 
fraction (SVF), which can differentially express these receptors. The purpose of this 
thesis is to further develop our understanding of how GH-, IGF-1-, and insulin-induced 
signaling affect adiposity in a WAT depot-specific manner. The original aims of this 
thesis were to: 1) use quantitative polymerase chain reaction (qPCR) to compare the 
expression of the receptors of the above hormones (GH, IGF-1, and insulin) in the SVF 
and adipocyte portions of the most commonly studied WAT depots in wildtype (WT) 
mice (subcutaneous, epididymal, retroperitoneal, and mesenteric), and 2) compare the 
expression of these receptors in the WAT depots of growth hormone antagonist (GHA) 
and WT mice. Unfortunately, due to low adipocyte RNA concentrations and purity, the 
first aim was adjusted to examine receptor RNA expression in whole WAT (as opposed 
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to isolated adipocytes) and SVF. No significant differences in receptor expression were 
observed in the first aim, but a trend toward greater insulin receptor (IR) RNA expression 
in the SVF of the epididymal depot compared to the SVF of the mesenteric depot was 
seen. The main significant finding of the second aim was that growth hormone receptor 
(GHR) was more strongly expressed in GHA mice than in WT mice in the mesenteric 
depot, a result that could be explained by differences in SVF cell populations in GHA 
mesenteric WAT. Thus, future studies should focus on examining differences in WAT 
immune cell populations in the two genotypes, as well as optimizing the process of RNA 
isolation from adipocytes to allow for a more clear comparison of the two portions. 
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 CHAPTER 1: INTRODUCTION 
Due to the rise in the rates of obesity and associated complications in recent 
decades, interest in adipose tissue (AT) research has increased.  Once considered an 
organ whose sole functions were energy storage and the cushioning of organs, results 
presented in recent years have revealed that AT is much more complicated than initially 
thought. For example, AT is now considered to possess potent endocrine function.  White 
(W) AT, the most abundant type of AT and the subject of this thesis, communicates with 
other cells to maintain energy balance through adipokines (hormones secreted by WAT) 
such as leptin (Zhang, Proenca et al. 1994), adiponectin (Nakano, Tobe et al. 1996), and 
resistin (Steppan, Bailey et al. 2001). In addition to its ability to produce and secrete 
hormones of its own, WAT is also affected by hormones including insulin (Dimitriadis, 
Mitrou et al. 2011), insulin-like growth factor-1 (IGF-1)  and growth hormone (GH) 
(Ottosson, Vikman-Adolfsson et al. 1995) through cell surface receptors specific for 
these hormones on the cells within the tissue. Furthermore, as revealed by transgenic 
mouselines, hormones can act on WAT in a depot-dependent manner (Berryman, List et 
al. 2011), adding another layer of complexity to WAT. As a result, it is necessary to study 
WAT and obesity in terms of these hormonal interactions and anatomical differences.  To 
that end, the goal of this thesis is to better understand the expression levels of several 
hormone receptors known to influence WAT mass and composition in a depot-specific 
manner. 
1.1: Metabolic functions of WAT 
 The classical function of WAT, an energy reservoir, is carried out by the 
adipocyte, a cell with a unilocular, large lipid droplet within WAT that maintains energy 
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balance of the organism through the storage and release of fatty acids (Cinti 2005). 
During times of excess energy intake, the size of the lipid droplet within the adipocyte 
and the overall WAT mass increases; during times when energy intake is inadequate, the 
WAT stores decrease. The storage of dietary fats occurs through the activity of the 
enzyme lipoprotein lipase, which hydrolyzes lipoprotein triglycerides, allowing for the 
uptake of fatty acids and the esterification of glycerol 3-phosphate (Frayn, Karpe et al. 
2003).  De novo lipogenesis also occurs in WAT to convert excess carbohydrate to lipids 
(Acheson, Schutz et al. 1988). Through lipolysis, which relies on hormone sensitive 
lipase (HSL) (Fredrikson, Stralfors et al. 1981) and adipose triglyceride lipase (ATGL) 
(Zimmermann, Strauss et al. 2004), stored triglycerides in WAT are broken down to 
provide energy (Hales, Luzio et al. 1978).   
The discovery of leptin in 1994 brought the discovery that AT is an endocrine 
organ that exerts its effects on other tissues through the secretion of adipokines (Zhang, 
Proenca et al. 1994). Leptin is produced primarily in WAT (but also in other tissues to a 
lesser extent), with its serum concentrations shown to be positively correlated to the 
amount of AT (Considine, Sinha et al. 1996; Ostlund, Yang et al. 1996). Leptin has many 
functions, with the primary one being its ability to inhibit food intake through its 
targeting of areas of the brain involved in appetite (Stephens, Basinski et al. 1995). Since 
the discovery of leptin, many other adipokines with widely varying functions have been 
discovered, providing evidence that WAT is a much more interactive organ than 
previously thought. Another well-studied adipokine is adiponectin, which, in contrast to 
leptin, negatively correlates with adiposity (Yamamoto, Hirose et al. 2002). Adiponectin 
is thought to protect against the development of obesity, diabetes, and cardiovascular 
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disease through its anti-inflammatory properties (Ouchi, Kihara et al. 1999; Yokota, 
Oritani et al. 2000; Ryo, Nakamura et al. 2004). Importantly, adiponectin is insulin-
sensitizing through its suppression of hepatic glucose production (Berg, Combs et al. 
2001).   
Another more recent role of WAT is its ability to alter the body’s inflammatory 
state. That is, inflammation plays a role in the metabolic processes of WAT, particularly 
in obese individuals. This chronic, low-grade inflammation results from increased 
populations of immune cells in WAT, particularly infiltrating inflammatory macrophages 
(Weisberg, McCann et al. 2003). The presence of inflammation in obese WAT was first 
reported in 1993, when it was noted that TNF-α expression is increased in the WAT of 
obese mice (Hotamisligil, Shargill et al. 1993). The inhibition of TNF-α resulted in an 
improvement in insulin resistance, demonstrating inflammation’s link to glucose 
homeostasis (Hotamisligil, Arner et al. 1995). It has been found that ~59% of mRNA 
transcripts in obese WAT are transcripts from inflammation-related genes; furthermore, it 
has been shown that these changes in expression positively correlate with the 
development of insulin resistance (Xu, Barnes et al. 2003). Inflammation is thought to be 
linked to insulin resistance in part through inflammatory cytokines’ activation of c-Jun N-
terminal kinase (JNK), which phosphorylates and inhibits IRS-1 (insulin receptor 
substrate 1), inhibiting the tyrosine kinase activity of the insulin receptor (IR) 
(Hotamisligil, Peraldi et al. 1996; Hirosumi, Tuncman et al. 2002) (see figure 1 for a 
summary of how TNF-α inhibits insulin-induced signaling). Thus, the inflammatory 
status of WAT is an important feature of the tissue that impacts the overall health of the 
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organism, and the resultant metabolic dysfunction caused by WAT inflammation is an 
area that requires further investigation. 
 
 
Figure 1. TNF-α’s inhibition of insulin-induced signaling. Binding of TNF-α to the TNF-
α receptor results in the phosphorylation of JNK and of IRS-1, thus inhibiting insulin’s 
action. Furthermore, TNF-α-induced signaling results in activation of inhibitor kappa 
beta kinase beta (IKK), followed by translocation of activator protein 1 (AP-1) and 
nuclear factor κβ (NF-κβ) to the nucleus, resulting in an increase in inflammatory 
cytokine production. Used with permission (Carter-Kent, Zein et al. 2008). 
 
 1.2: Mouse and human WAT depots 
1.2.1: Depot locations and classifications 
The distribution of WAT is organized into several distinct areas or “depots”. 
These depots are considered either “subcutaneous” or “visceral”, depending on their 
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anatomical location (Cinti 2012). In mice, the primary subcutaneous depots are located 
directly under the skin both anteriorly or posteriorly, which includes the inguinal depot, 
the most commonly studied subcutaneous depot (Cinti 2005).  In addition to inguinal, 
other depots of the posterior subcutaneous adipose include dorso-lumbar and gluteal; 
depots of the anterior subcutaneous adipose include the interscapular, subscapular, 
axillary, and cervical depots (Cinti 2012). The main visceral depots in mice are located 
intraabdominally and include the mesenteric (surrounding the intestines), retroperitoneal 
(behind the kidneys), and perigonadal (surrounding the testes-“epididymal”-or ovaries-
“periovarian”) depots (Cinti 2005) (See Figure 2 for an overview of adipose depots in 
mice). However, the mesenteric depot is considered the only “true” visceral depot 
because it drains into the portal vein (Catalano, Stefanovski et al. 2010). These four 
depots - inguinal, perigonadal, retroperitoneal, and mesenteric - are the depots most 
commonly studied in mice.  
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Figure 2. Locations of most commonly studied WAT depots in male mice.  The inguinal 
depot (SUBQ) is the subcutaneous depot primarily studied and is located beneath the skin 
in the groin region. While mesenteric, retroperitoneal, and epididymal adipose depots are 
all considered intraabdominal (IA), only one, mesenteric, is considered “true visceral” 
due to its drainage into the portal vein to the liver. The location of the kidney is 
designated with a “K”. Used with permission (Sackmann-Sala 2010; Berryman, List et al. 
2011) 
 
In humans, the subcutaneous adipose depots include the abdominal, gluteal, and 
femoral depots (Wronska and Kmiec 2012). The intraabdominal depots in humans are the 
gonadal, retroperitoneal, mesenteric, pericardial, and omental depots (Cinti 2005; 
Bjorndal, Burri et al. 2011). Similarly to mice, only certain intraabdominal depots may 
actually be classified as visceral due to their drainage into the portal vein; in humans, 
these are the mesenteric and omental depots (Foster and Pagliassotti 2012). Much of the 
metabolic dysregulation seen in visceral obesity is attributed to the effects on hepatocytes 
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of fatty acids and adipokines secreted from these visceral depots (Hotamisligil, Peraldi et 
al. 1996). See Figure 3 for an overview of adipose depots in humans. 
 
Figure 3. Locations of WAT depots in humans. Subcutaneous depots include the 
subcutaneous abdominal, gluteal, and femoral. Visceral depots include the epicardial, 
mesenteric, omental, retroperitoneal, and gonadal depots. However, due to their drainage 
into the portal vein, only the epicardial, omental, and mesenteric depots are considered 
true visceral depots. Modified and used with permission (Awada, Parimisetty et al. 2013) 
 
There are several additional differences between human and rodent AT depots.  
For example, the pericardial depot, which is composed of paracardial and epicardial fat, 
is associated with the heart (Bjorndal, Burri et al. 2011; Fitzgibbons and Czech 2014); 
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there is evidence to suggest that this depot exhibits some characteristics of brown fat 
(Cheung, Gertow et al. 2013; Sacks, Fain et al. 2013).  Previously, it was thought that 
rodents lack this depot (Marchington, Mattacks et al. 1989); however, recently epicardial 
AT has been identified in mice, particularly in those that are high-fat diet-fed 
(Yamaguchi 2015). The omental depot, which begins at the stomach and spleen and 
extends into the abdomen, is much less developed in rodents (Cinti 2005; Bjorndal, Burri 
et al. 2011). 
1.2.2: Depot-specific differences 
WAT depots differ in many aspects, leading to their classification as 
subcutaneous or visceral. As mentioned previously, while intraabdominal depots are 
frequently referred to as “visceral”, only those depots that drain into the portal vein may 
be considered “true” visceral. For purposes of this thesis, only these ‘true’ depots will be 
referred to as visceral. Many studies regarding depot-specific differences have been 
conducted in a variety of models, including obese and lean human and rodent models.  
For example, adipokine output is depot-dependent.  As expected, visceral AT shows 
higher expression of proteins linked to the development of insulin resistance, such as 
resistin (Steppan, Bailey et al. 2001; Milan, Granzotto et al. 2002). In contrast, 
subcutaneous AT seems to be more involved in the production of adiponectin (Lihn, 
Bruun et al. 2004), which promotes insulin sensitivity and is associated with leanness 
(Berg, Combs et al. 2001; Fruebis, Tsao et al. 2001; Yamauchi, Kamon et al. 2001). 
Levels of insulin-induced intracellular signaling proteins seem to suggest that visceral AT 
is more metabolically active than subcutaneous AT (Lefebvre, Laville et al. 1998; 
Laviola, Perrini et al. 2006; Veilleux, Blouin et al. 2009); however, there is conflicting 
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literature regarding mitochondrial respiratory capacity (Deveaud, Beauvoit et al. 2004). 
Conflicting reports also exist regarding TNF-α expression in visceral and subcutaneous 
depots (Montague, Prins et al. 1998; Hube, Birgel et al. 1999; Mohamed-Ali, Goodrick et 
al. 1999; Winkler, Kiss et al. 2003).  There are many other ways in which depots differ.  
Table 1 and Table 2 provide additional comparisons of the general characteristics of 
subcutaneous and visceral AT and depot-specific mRNA and protein expression levels, 
respectively. 
 
 
Table 1.  A comparison of general characteristics of subcutaneous as compared to  
visceral WAT depots in humans and various rodent models. 
 
Characteristic Subcutaneous (as compared 
to visceral) 
Reference 
Adipocyte susceptibility 
to apoptosis 
↓ (human subjects) (Niesler, Siddle et al. 1998) 
Adipocyte size ↑ (human subjects) (Lundgren, Buren et al. 
2004) 
Inflammatory cell 
populations  
↓ (mast cells in obese 
C57BL/6 mice) 
↓ (macrophages in human 
subjects) 
(Altintas, Azad et al. 2011) 
 
(Curat, Wegner et al. 2006) 
Capillary density per 
adipocyte 
↑ (human subjects) (Gealekman, Guseva et al. 
2011) 
Angiogenesis ↑ ( human subjects) (Gealekman, Guseva et al. 
2011) 
Presence of crown-like 
structures (CLS)a  
↓ (C57BL/6 mice) (Altintas, Azad et al. 2011)-  
Mitochondrial respiratory 
capacity 
↑ (C57BL/6 mice) 
 
↓ (Wistar rats) 
(Schottl, Kappler et al. 
2014)- 
(Deveaud, Beauvoit et al. 
2004)- 
aclusters of macrophages around an adipocyte 
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Table 2.  A comparison of gene and protein expression in subcutaneous as compared to 
visceral WAT depots in humans and various rodent models. 
Characteristic Subcutaneous (as compared to 
visceral) 
Reference 
Leptin  ↑ (mRNA, human subjects) 
 
 
(Masuzaki, Ogawa et al. 1995) 
(Montague, Prins et al. 1997) 
(Lefebvre, Laville et al. 1998) 
PPARγ  ↓ (mRNA, human subjects) (Lefebvre, Laville et al. 1998) 
Interleukin-6   ↓ (protein in incubations of 
adipocytes and AT, human 
subjects) 
(Fried, Bunkin et al. 1998) 
(Fain, Madan et al. 2004) 
 
Resistin  ↓ (mRNA, Zucker rats) (Milan, Granzotto et al. 2002) 
Adiponectin  ↑ (mRNA, human subjects) (Lihn, Bruun et al. 2004) 
Growth hormone 
receptor 
↓  (mRNA, human subjects) (Erman, Veilleux et al. 2011)  
Insulin receptor  ↓ (mRNA, human subjects) (Lefebvre, Laville et al. 1998) 
Collagen alpha-
3(VI) (COL6A3) 
↓ (mRNA, human subjects) (Pasarica, Gowronska-Kozak et 
al. 2009) 
GLUT4 ↓ (mRNA, human subjects) (Veilleux, Blouin et al. 2009) 
TNF-α ↑ (mRNA, human subjects) 
↑ (protein, human subjects) 
 
↑/↓ (mRNA in cultured 
adipocytes) 
 
Undetectable (protein in 
subcutaneous AT in vivo human 
subjects) 
(Hube, Birgel et al. 1999) 
(Winkler, Kiss et al. 2003) 
 
(Montague, Prins et al. 1998) 
 
 
(Mohamed-Ali, Goodrick et al. 
1999) 
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1.3: WAT cell types 
In addition to the aforementioned depot differences, the cellular composition of 
WAT depots varies greatly depending on the anatomical location of the specific depot. 
The cells that make up WAT depots are divided into two categories: mature adipocytes 
and cells of the stromal vascular fraction (SVF). It has been estimated that white 
adipocytes make up only 50% of WAT, with the remaining being cells of the SVF 
(Bukowiecki, Collet et al. 1982).  The adipocyte and SVF portions may be separated and 
isolated through the use of collagenase to digest AT (See figure 4 for an overview of how 
the SVF is isolated and the cellular components that constitute the SVF.) As mentioned 
previously, white adipocytes function to store and release triacylglyceride, depending on 
the organism’s energy state, as well as secrete adipokines (Hales, Luzio et al. 1978). The 
SVF is a group of diverse cells that includes mesenchymal stem cells, endothelial cells, 
endothelial precursor cells, fibroblasts, and a variety of immune cells (Cancello and 
Clement 2006; Riordan, Ichim et al. 2009). The SVF portion has been shown to secrete 
adipokines of different varieties and amounts compared to adipocytes (Fain, Madan et al. 
2004). Mesenchymal stem cells are the precursors to pre-adipocytes that eventually 
become functional mature adipocytes, but are considered pluripotent and can also be 
induced to differentiate into chondrogenic, myogenic, and osteogenic cell lines (Riordan, 
Ichim et al. 2009). The CD34+/CD31- endothelial precursor cells in the SVF differentiate 
in vitro to endothelial cells and participate in revascularization of an ischemic hind limb 
in nude mice (Miranville, Heeschen et al. 2004). Among the many cell types in the SVF, 
perhaps the most well studied are the immune cells due to their involvement in the 
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development of insulin resistance. The following section will explore the association 
between obesity and immune cells. 
 
 
 
Figure 4. Isolation of cellular components of WAT. Excised adipose tissue may be 
broken down into adipocytes and stromal vascular cells by incubating the tissue with 
collagenase. Following centrifugation, mature adipocytes float to the top and the stromal 
vascular cells form a pellet. The stromal vascular fraction (SVF) is composed of a variety 
of cell types, including mensenchymal stem cells, endothelial cells, endothelial precursor 
cells, fibroblasts, and various immune cells. 
 
It has been shown that immune cells play many roles in metabolism, including 
adipose tissue expansion, lipolysis, and non-shivering thermogenesis (Ferrante 2013). 
Immune cells present in adipose tissue include cells of both the innate and adaptive 
immune system:  adipose tissue macrophages (ATMs),  natural killer T (NKT) cells, 
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invariant NKT (iNKT) cells, neutrophils, dendritic cells, mast cells, B cells, and CD3+, 
CD4+, CD8+, and regulatory (Treg) T cells (Ferrante 2013). All of these cell populations 
exhibit an increase or decrease in number during the AT expansion that occurs during 
obesity (Ferrante 2013). See Table 3 for an overview of the changes in immune cell 
populations that occur during AT expansion. 
 
Table 3. Differences in immune cell populations in obese as compared to lean  WAT 
Immune cell Obese (as compared to lean) Reference 
Mast cells ↑ (C57BL/6 mice, increases primarily 
in visceral) 
(Altintas, Azad et al. 2011)  
Dendritic cells  ↑  (humans, positively correlates with 
AT mass) 
 
↑  (humans and mice, correlates with 
insulin resistance) 
(Bertola, Ciucci et al. 2012) 
 
 
(Wu, Gower et al. 2009) 
Eospinophils ↓  (C57BL/6 mice, correlates 
negatively with adiposity) 
(Wu, Molofsky et al. 2011)  
Neutrophils ↑ (human subjects, positively 
correlates with adiposity) 
(Dixon and O'Brien 2006) 
M1:M2 
macrophage ratio  
↑ (C57BL/6 mice, M1 and M2 
macrophages increase--M1 increases 
most) 
(Fujisaka, Usui et al. 2009)  
CD8+  T cells ↑ (C57BL/6 mice) 
 
(Rausch, Weisberg et al. 
2008; Nishimura, Manabe 
et al. 2009)  
CD4+ T cells  ↓ (C57BL/6 mice) 
 
↑ (human subjects, correlates with 
waist size) 
(Nishimura, Manabe et al. 
2009) 
(Kintscher, Hartge et al. 
2008) 
Regulatory T cells   ↓ (C57BL/6 mice) 
 
(Nishimura, Manabe et al. 
2009)  
(Feuerer, Herrero et al. 
2009) 
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1.4: Comparison of adipocytes and SVF 
As would be expected, the adipocytes and cells that constitute the SVF fraction 
differ in terms of protein expression.  For example, it has been shown that both the 
adipocyte and SVF portions of AT secrete a variety of adipokines but differ in the type 
and amount (Fain, Madan et al. 2004). In general, the SVF secretes a higher 
concentration of inflammatory cytokines, such as tumor necrosis factor α (TNF-α) and 
interleukin 6 (IL-6) (Fain, Madan et al. 2004), than the adipocyte portion (Zeyda, Farmer 
et al. 2007). Interestingly, expression of nuclear envelope proteins Lamins A & C, which 
are linked with inherited partial lipodystrophies (Garg and Agarwal 2009), is elevated in 
the SVF of only subcutaneous AT (Peinado, Jimenez-Gomez et al. 2010). This is 
particularly of interest because it demonstrates how proteins may be differentially 
expressed in not only depots, but also in the two cellular fractions of AT. 
Since expression levels of a variety of genes can vary depending on depot as well 
as the SVF and adipocyte fractions, it is important to evaluate different depots and the 
different fractions in order to improve our understanding of the function of adipose tissue 
components. For example, a study by Peinado et al. suggests that the primary differences 
in subcutaneous and visceral depots and the resultant association of excess visceral 
adipose to metabolic disorders are due to the secretion of SVF proteins (Peinado, 
Jimenez-Gomez et al. 2010). It should be noted that in this study, the expression of the 
adipokines, omentin and visfatin, are elevated in the SVF of visceral AT compared to the 
SVF of subcutaneous AT (Peinado, Jimenez-Gomez et al. 2010). However, when the 
expression of these adipokines in whole tissue subcutaneous and visceral samples is 
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compared, no differences are observed (Peinado, Jimenez-Gomez et al. 2010). 
Furthermore, the visceral and subcutaneous AT adipocytes from lean individuals show 
highly similar protein expression in contrast to the SVF portion, which show significant 
differences (Peinado, Jimenez-Gomez et al. 2010). This study emphasizes the importance 
of comparing the SVF and adipocyte portions in addition to whole tissue when 
comparing protein expression between two depots. Refer to Table 4 for additional 
comparisons of SVF and adipocyte characteristics. 
 
Table 4. A comparison of adipocyte and SVF portions of WAT depots in humans. 
 
 
In addition to the differences in expression shown in Table 4, adipocytes and cells 
of the SVF differentially express receptors for hormones related to growth and 
metabolism. For example, adipocytes as well as some of the cells of the SVF, such as AT 
macrophages, are known to express growth hormone receptor (GHR) (Gavin, Saltman et 
al. 1982; Smith, Benghuzzi et al. 2000). GH’s interaction with the GHR on macrophages 
has been shown to inhibit the cells’ expression and secretion of IL-1β, thus inhibiting the 
Characteristic  Adipocytes (as compared 
to SVF) 
Reference 
Leptin  ↑ (protein, human subjects) 
 
↑ (mRNA, human subjects) 
(Fain, Madan et al. 2004) 
(Masuzaki, Ogawa et al. 
1995) 
Adiponectin  ↑ (protein, human subjects) (Fain, Madan et al. 2004) 
Tumour necrosis factor-α  ↓ (protein, human subjects) (Fain, Madan et al. 2004) 
Interleukin-6  ↓ (protein, human subjects) (Fain, Madan et al. 2004) 
Lamin A & C ↓ (protein, human subjects) (Peinado, Jimenez-Gomez 
et al. 2010) 
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differentiation of pre-adipocytes (Lu, Kumar et al. 2010). Likewise, adipocytes are 
known to possess the insulin-like growth factor 1 receptor (IGF-1R) and IR (Berhanu, 
Kolterman et al. 1983; Kloting, Koch et al. 2008); however, there is little available data 
to suggest the presence or absence of these receptors in SVF cells. Additional information 
related to these hormones and their receptors will be discussed in the subsequent section 
1.5: Growth Hormone Receptor 
1.5.1: GHR structure 
GH is a 22,000 kDa polypeptide hormone necessary for the induction of postnatal 
growth in mammals (Edens and Talamantes 1998). GH is secreted from the anterior 
pituitary in a pulsatile manner, with the largest pulses occurring at night (Khan, Sane et 
al. 2002). GH exerts its effects on target tissues through specific interactions with the 
GHR on the surface of cells to induce an intracellular signaling cascade, as will be 
described in detail below (Edens and Talamantes 1998).  The GHR weighs approximately 
100-130 kDa depending on the species of origin and is ~620 amino acids in length 
(Edens and Talamantes 1998). The mature receptor is composed of an extracellular 
domain at the N terminus, where the GH molecule binds, of ~245 amino acids, a 
transmembrane domain of 24 amino acids, and an intracellular domain of ~350 amino 
acids at the C terminus, where signaling occurs  (Edens and Talamantes 1998). The GHR 
is considered a class 1 cytokine receptor in that it utilizes the Janus-kinase signal 
transducers and activators of transcription (JAK-STAT) signaling pathway ((Brooks and 
Waters 2010).  
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1.5.2: GHR-induced signaling 
GHR exists in a pre-dimerized form (Brown, Adams et al. 2005) that becomes 
activated by binding GH at its two GHR binding sites (Argetsinger, Campbell et al. 1993; 
Brooks and Waters 2010). Upon GH binding, the intracellular domains of the GHR 
rotate, activating Janus kinase 2 (JAK2) and Src family kinases associated with the 
intracellular domain of the GHR  (Brown, Adams et al. 2005; Brooks and Waters 2010; 
Brooks, Dai et al. 2014). As a result of this activation, cross-phosphorylation of the 
tyrosine residues of the GHR cytoplasmic tails occurs (Brown, Adams et al. 2005). 
Following the recruitment of additional signaling molecules, STAT5 a and b become 
phosphorylated and dimerize, allowing them to enter the nucleus to bind to STAT 
responsive elements in the enhancers of targeted genes that influence growth and 
metabolism. Activation, synthesis, and secretion of IGF-1 also occurs in most cells as a 
result of GH action (Herrington, Smit et al. 2000). See figure 5 (on page 32 of this thesis) 
for an overview of GH-induced signaling. Important to this thesis is the fact that, WAT is 
one of many tissues that are well established to possess cells that express GHR, which is 
described more fully in the subsequent section. GH-induced signaling in the adipocyte 
increases basal lipolysis and improves AT’s response to lipolytic catecholamines 
(Ottosson, Lonnroth et al. 2000). However, despite actions promoting lipolysis and 
reduction of AT, GH-induced signaling has a diabetogenic effect (Bornstein, Taylor et al. 
1969) induced by its suppression of insulin signaling (Adamson and Efendic 1979). One 
of the mechanisms by which GH-induced signaling suppresses insulin sensitivity is 
elucidated in a publication by del Rincon et al. (del Rincon, Iida et al. 2007) In brief, GH-
induced signaling upregulates mRNA and protein expression of the p85a regulatory 
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subunit of phosphatidyl inositol 3’ kinase (PI3K), a kinase crucial to the insulin signaling 
pathway (del Rincon, Iida et al. 2007). Other mechanisms include reduction of insulin 
receptor, insulin receptor substrate 1 (IRS-1), and PI3K levels (Thirone, Carvalho et al. 
1997; Johansen, Laurino et al. 2005), as well as reduction in insulin-stimulated 
phosphorylation of many insulin substrates (Thirone, Carvalho et al. 1997).   
1.5.3: GHR expression in WAT 
GH exerts its metabolic effects by interacting with the GHR in many tissues, with 
the primary ones being skeletal muscle, liver, and AT. GHR in AT has been shown to be 
expressed particularly in isolated adipocytes (Vikman, Carlsson et al. 1991) and pre-
adipocytes (Gerfault, Louveau et al. 1999). However, GHR is also expressed in AT 
macrophages (Lu, Kumar et al. 2013), but other stromal vascular cell types isolated from 
AT, to the best of my knowledge, have not been specifically investigated.  Like many 
molecules, GHR is expressed differentially in visceral and subcutaneous adipose depots. 
Studies have shown that rats have higher GHR expression in adipocytes from epididymal 
depots than in adipocytes from retroperitoneal or subcutaneous depots (LaFranchi, Hanna 
et al. 1985).  Similarly, in pigs, adipocytes from the omental depot have higher GHR 
expression than adipocytes from perirenal and subcutaneous fat (Brameld, Atkinson et al. 
1996). Furthermore, a study in humans showed greater RNA expression in the abdominal 
depot compared to the gluteal (subcutaneous) depot (Karastergiou 2013). 
1.6: IGF-1R and IR 
1.6.1: IGF-1R and IR structure 
IGF-1 is a 70 amino acid polypeptide that mediates at least some of the anabolic 
and mitogenic activities of GH (Laron 1999). IGF-1 secretion from the liver as well as 
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paracrine secretion from other tissues is dependent on GH-induced signaling (Laron 
2001). Insulin is a 55 amino acid dipeptide hormone produced by the beta cells of the 
pancreas that stimulates the translocation of the insulin-sensitive glucose transporter 4 
(GLUT4) to the cell membrane of fat and muscle cells, allowing for the uptake of glucose 
(Birnbaum 1989; Wilcox 2005).  As IGF-1’s name implies, the protein has a very similar 
structure to that of proinsulin, the precursor to insulin; indeed, amino acids 1 to 29 of 
IGF-1 share homology with insulin’s B chain and amino acids 42-62 share homology 
with insulin’s A chain (Rinderknecht and Humbel 1978). 
The receptors utilized by IGF-1 and insulin, IGF-1R and IR, respectively, have 
high structural similarity; in fact, it is often difficult to discern the biological effects 
mediated by each specifically (Kim and Accili 2002). Both receptors have beta-alpha-
alpha-beta subunit structure with alpha and beta subunits of 88 kDa and 67 kDa, 
respectively; they also have similar amino acid composition, with sequences 41-84% 
alike depending on domain (Fujita-Yamaguchi, LeBon et al. 1986; De Meyts and 
Whittaker 2002). Furthermore, the two receptors  are known to form heterodimers 
between each other that bind IGF-1 with higher affinity and insulin with a lower affinity 
(Soos, Field et al. 1993), as seen in figure 5. Both the IGF-1R and IR belong to the 
receptor tyrosine kinase family; however, unlike other receptor tyrosine kinases, they 
exist on the cell in a pre-dimerized state rather than dimerizing in response to ligand 
binding (Heldin and Ostman 1996; Hubbard and Till 2000).  
1.6.2: IGF-1R- and IR-induced signaling 
Similarly to GH-induced signaling, IGF-1 binding results in cross-
phosphorylation of the IGF1-R, leading to a signaling cascade initiated by tyrosine 
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phosphorylation of substrates including the IRS 1-4 (Sun, Rothenberg et al. 1991; Pelicci, 
Lanfrancone et al. 1992; Patti, Sun et al. 1995; Lavan, Lane et al. 1997) (for simplicity, 
only IRS 1 is shown in figure 5). IRS 1-4 then interact with proteins possessing SH2 
domains, for example,  the p85 regulatory subunit of PI3K, growth factor receptor 
binding protein 2 (Grb2), and SHP-2/Syp, a protein tyrosine phosphatase (Dupont and 
Holzenberger 2003). Tyrosine phosphorylation of each of these substrates results in the 
induction of signaling cascades associated with cell proliferation, differentiation, glucose 
transport, and the prevention of apoptosis (Dupont and Holzenberger 2003). 
Activation of the IR by insulin modulates the uptake of glucose into cells by 
insulin-responsive GLUT4 (Birnbaum 1989). Insulin’s binding to the IR induces cross-
phosphorylation of residues on proteins associated with the intracellular domains of the 
IR (IRS 1-4), followed by recruitment of proteins such as the p85 regulatory subunit of 
PI3K (Summers, Whiteman et al. 2000). Activation of the Akt/PKB signaling pathway 
then results in GLUT4 translocation to the cell membrane (Ishiki, Randhawa et al. 2005). 
As discussed previously, insulin’s actions can be inhibited by GH signaling; thus, 
chronically elevated levels of GH have a diabetogenic or anti-insulin effect known to be 
induced through several mechanisms (Thirone, Carvalho et al. 1997; Johansen, Laurino et 
al. 2005; del Rincon, Iida et al. 2007). See Figure 5 for an overview of insulin- and IGF-
1-induced signaling.  
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Figure 5. Overview of GH-, insulin-, and IGF-1-induced signaling. The insulin and IGF-
1 receptors are highly similar, allowing for some cross-reactivity in binding. Binding of 
either receptor results in cross-phosphorylation of the receptor, followed by 
phosphorylation of IRS, allowing IRS to bind to the p85 regulatory subunit of PI3K. The 
final outcome of this pathway is the translocation of GLUT4 to the cell surface and the 
upregulation of genes related to glycogen synthesis and inhibition of lipolysis. The 
binding of GH to the GHR results in cross-phosphorylation of the receptor, inducing 
rotation of the intracellular domains and activation of JAK2 and Shc. Phosphorylation of 
transcription factor STAT5 results in translocation of this molecule to the nucleus, where 
it regulates genes related to cell proliferation and growth, as well as production of IGF-1. 
Chronically elevated GH is known to induce diabetogenic effects through the inhibition 
of insulin signaling (not shown). Used with permission (Trobec, von Haehling et al. 
2011). 
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1.6.3: IGF-1R and IR expression in WAT 
As with GHR, IGF-1R has been detected in isolated adipocytes and pre-
adipocytes from pigs (Gerfault, Louveau et al. 1999) as well as in human adipocytes in 
culture (Kern, Svoboda et al. 1989). However, several studies have failed to detect IGF-
1R in both pig (Richardson, Hausman et al. 1994) and human adipocytes (DiGirolamo, 
Eden et al. 1986; Bolinder, Lindblad et al. 1987). Regarding the functions of IGF-1-
induced signaling in AT, IGF-1 has been shown to be involved in pre-adipocyte 
differentiation into adipocytes (Smith, Wise et al. 1988). Furthermore, IGF-1R knockout 
mouse studies have shown that IGF-1 plays a role in regulating adiposity (Kloting, Koch 
et al. 2008). Specifically, in IGF-1R knockout mice, adipose mass is increased and the 
mean adipocyte size is increased compared to controls. These differences are exacerbated 
in perigonadal depots compared to subcutaneous depots (Kloting, Koch et al. 2008), 
which implies potential depot differences in the expression of this receptor. 
It is well known that IR is expressed in adipocytes, due its role in the stimulation 
of GLUT4 translocation to the cell membrane; however, IR protein has also been shown 
to be expressed in 3T3-L1 preadipocytes (Reed, Kaufmann et al. 1977). Depot-specific 
differences in insulin signaling molecules have been noted as well (Laviola, Perrini et al. 
2006); that is, in non-obese, non-diabetic humans, expression of insulin signaling 
molecules is higher in the omental depot than in the subcutaneous depot (Laviola, Perrini 
et al. 2006).  From my literature search, it appears that neither IGF-1R nor IR expression 
levels have been investigated in SVF cells, which suggests that this area requires further 
investigation. 
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1.7: Summary 
Taken together, the topics discussed in this chapter emphasize the importance of 
investigating not only depot-specific differences, but also differences observed in SVF of 
WAT. This chapter summarized specific characteristics of subcutaneous and visceral 
WAT depots as well as how they differentially express many proteins, in addition to 
providing an introduction to GH-, IGF-1-, and insulin-induced signaling in WAT. The 
following chapter will provide further background on the depot-specific impact GH-, 
IGF-1-, and insulin-induced signaling have on WAT using data generated from mouse 
lines, focusing on unpublished data that have been generated in our laboratory.  
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CHAPTER 2: BACKGROUND INFORMATION AND EXPERIMENTS 
2.1.: Evidence for a depot-specific impact of GH on WAT 
 Many experiments conducted in our laboratory using GH transgenic lines suggest 
a depot-specific effect of GH on WAT. Two transgenic models in particular have been 
instrumental in deriving the depot-specific effects of GH on adiposity: 1) the GH receptor 
null (GHR -/-) mice, which lack functional GHR and are dwarf, obese, insulin-sensitive, 
and long-lived (List, Sackmann-Sala et al. 2011); and 2) the GH receptor antagonist 
(GHA) mice, which produce a GH antagonist that functions to limit GH-induced 
signaling, resulting in obesity, but retains normal insulin levels and lifespan (Coschigano, 
Holland et al. 2003). These mouse lines allow us to investigate the effects of adiposity 
seen when GH signaling is reduced (GHA mice) or removed (GHR -/- mice). 
 GHR -/- mice were first produced in 1997 through disruption of the GHR/BP 
gene by homologous recombination of a DNA fragment into exon 4 of the mouse GHR 
gene  (Zhou, Xu et al. 1997). Subsequent investigation has revealed that WAT depots are 
affected differentially due to the ablation of GHR. That is, while GHR -/- mice have 
increased adiposity, not all fat depots are equally affected.  Specifically, the subcutaneous 
depots are enlarged preferentially compared to intraabdominal depots (Berryman, List et 
al. 2011), suggesting that GH affects WAT to a greater extent in the subcutaneous depot. 
The preferential enlargement of the subcutaneous depot in GHR -/- mice and other mouse 
models of GH disruption has been noted by numerous other studies (Berryman, List et al. 
2004; Meyer, Korthaus et al. 2004; Berryman, List et al. 2010). This trend (an 
enlargement of the subcutaneous depot and impairment in development of the 
paraovarian depot) has also been shown for female GHR-/- mice as compared to WT 
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(Flint, Binart et al. 2006).  Subsequent in vitro experiments demonstrate that adipocytes 
from the parametrial depot are significantly impaired in terms of proliferation and 
differentiation, while adipocytes from the inguinal depot show no impairment (Flint, 
Binart et al. 2006).  This suggests that the ablation of GH action has a greater effect on 
the parametrial depot. GHR -/- mice also show reduced expression of GLUT4 protein in 
the inguinal depot compared to wild-type mice, indicating that the removal of GH 
signaling affects insulin-induced translocation of GLUT4 (Sackmann-Sala, Berryman et 
al. 2014). Furthermore, data have suggested that visceral fat in GHR -/- mice may not 
have the negative effects observed in wild-type mice, as the removal of visceral fat does 
not result in improvement in insulin-sensitivity as observed in wild-type controls 
(Masternak, Bartke et al. 2012). Thus, GHR-/- mice show several important differences 
in AT distribution and function compared to WT mice. 
 GHA mice, which are used in Aim 2 of this thesis, were first produced in 1991 
through pronuclear microinjection of a bovine GH minigene with a mutation of a codon  
in the third alpha helix of the bovine GH (resulting in glycine 119 being replaced by 
lysine) (Chen, White et al. 1991). Thus, the introduced antagonist competes with pituitary 
or endogenous GH for GHR binding sites, reducing, but not eliminating, GH-induced 
signaling. Similarly to GHR -/- mice, GHA mice possess a larger inguinal depot 
compared to WT mice (Berryman, List et al. 2004). A recent study examined the effects 
of high-fat feeding on WAT expansion in these mice (Yang, Householder et al. 2015). 
The GHA mice show a more dramatic expansion of WAT, particularly in the 
subcutaneous and perigonadal depots, but remain insulin sensitive and glucose tolerant 
with only slight increases in serum glucose levels. However, despite having decreased 
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GH signaling, GHA mice do not exhibit the same improvements in glucose homeostasis 
and lifespan extension seen in GHR -/- mice (Coschigano, Holland et al. 2003; Berryman, 
Lubbers et al. 2014). This difference has been attributed primarily to the fact that GHA 
mice possess only moderately reduced GH action, while GHR -/- mice possess total 
ablation of the GH action via the GHR (Berryman, Lubbers et al. 2014).  Another 
important feature of the GHA mice in comparison to non-transgenic littermate controls is 
that GH-specific binding in liver is elevated in GHA mice, while GH-specific binding in 
kidney is reduced (Chen, Chen et al. 1997). Thus, not all tissues respond in a similar 
fashion in GHA mice with respect to GHR tissue levels.  For a summary of 
characteristics of GHR -/- and GHA mice, see Table 5. 
 
Table 5. Summary of characteristics of GHR -/- and GHA mice. 
Genotype GHR -/-a GHAa 
GH signaling absent (Zhou, Xu et al. 1997) ↓ (Chen, Wight et al. 1991) 
(Chen, White et al. 1991) 
% fat mass ↑ 6 weeks of age - 2 years of age 
(Berryman, List et al. 2004) 
(Egecioglu, Bjursell et al. 2006) 
↑ 6 months of age (Berryman, 
List et al. 2004) 
Serum 
adiponectin 
↑ (Berryman, List et al. 2004) ↑ (Berryman, List et al. 2004) 
Serum leptin unchanged (Berryman, List et al. 
2004), unchanged (Egecioglu, 
Bjursell et al. 2006) 
↑ (Berryman, List et al. 2004) 
Serum IGF-1 20% WT level (Coschigano, 
Holland et al. 2003) 
75-80% WT level (Coschigano, 
Holland et al. 2003) 
Fasting serum 
insulin levels 
↓ (Coschigano, Holland et al. 
2003) 
unchanged (Coschigano, Holland 
et al. 2003) 
Fasting serum 
glucose levels 
↓ (Coschigano, Holland et al. 
2003) 
unchanged (Coschigano, Holland 
et al. 2003) 
Lifespan  ↑ (Coschigano, Holland et al. 
2003) 
unchanged (Coschigano, Holland 
et al. 2003; Berryman, Lubbers et 
al. 2014) 
a versus WT littermate controls 
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In addition to data generated from these genetically engineered mouse lines, 
several studies, including an honors thesis project by D. Bailey Miles from our 
laboratory, have attempted to directly compare adipose depot expression of GHR, IGF-
1R, and IR in normal C57Bl/6J mice.  The findings from these preliminary studies will be 
discussed in the subsequent sections. 
2.2: GHR mRNA expression in WAT 
A recent  study in our laboratory compared the mRNA expression of GHR, IGF-
1R, and IR in whole AT depots of 3 month-old and 9 month-old C57Bl/6J male mice 
(Miles 2009). Both age-related and depot-specific differences were observed in this 
study. In the mesenteric depot, GHR had a higher relative expression in the 9 month-old 
group compared to the 3-month old group (figures 6 and 7), either suggesting that GH-
induced intracellular signaling becomes more important in this depot as mice age or that 
the level of GHR increases with age to compensate for reduced GH levels.  
Depot-specific differences in GHR expression were also noted in the thesis.  The 
3 month-old group had higher GHR expression in the epididymal and retroperitoneal 
depots than in the subcutaneous and mesenteric depots (figure 6). In the 9 month-old 
group, the epididymal depot also showed higher GHR expression than the subcutaneous 
depot (figure 7). These results suggest that GH-induced intracellular signaling is more 
active in the epididymal depot, which is contrary to conclusions drawn from studies in 
GHR -/- and GHA mice, which show that subcutaneous adipose is most greatly affected 
by the reduction in GH signaling (Berryman, List et al. 2004). However, these results do 
match the proliferation and differentiation studies that have been performed by Flint et al 
(Flint, Binart et al. 2006).  Unfortunately, these studies only assessed GHR expression 
  39 
levels in whole tissue; thus, it is impossible to determine the adipocyte versus SVF 
contribution to this expression, which may explain the disconnect between the depot 
expression levels of GHR and the WAT phenotypes in these mice.  Further studies 
regarding the expression of GHR in wild type mice have been discussed extensively in 
chapter 1.   
2.3: IGF-1R mRNA expression in WAT 
In the thesis of D. Bailey Miles, expression of IGF-1R exhibited age-related 
differences as well (Miles 2009). IGF-1R mRNA had a relatively higher expression in the 
subcutaneous depot of the  9 month-old group compared to the 3 month-old group; 
conversely, the epididymal depot showed a relatively higher expression in the 3 month-
old group compared to the 9 month-old group (figures 6 and 7). These data are supported 
by a study using 8 month-old IGF-1R knockout mice, in which epididymal fat mass 
increased preferentially in these mice (Kloting, Koch et al. 2008).  
 WAT depot-specific differences in IGF-1R expression were observed in both age 
groups. In the 3 month-old group, IGF-1R was more strongly expressed in the epididymal 
depot compared to the subcutaneous depot (figure 6). In contrast, the 9 month-old 
groupshowed a heightened expression in the mesenteric depot compared to the 
retroperitoneal depot (figure 7). Positive correlations were also observed between IGF-1R 
and IR expression, supporting IGF-1R’s contribution to insulin signaling. Further studies 
regarding the expression of IGF-1R in wild type mice have been discussed extensively in 
chapter 1. 
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2.4: IR mRNA expression in WAT 
 Depot-specific differences in IR expression showed trends similar to those of the 
IGF-1R expression (Miles 2009). The 3 month-old mice had greater IR expression in the 
epididymal depot than in the subcutaneous and mesenteric depots. Also, the 
retroperitoneal depot had higher expression than the subcutaneous depot (figure 6). The 9 
month-old mice showed higher IR expression in the mesenteric depot compared to the 
subcutaneous and retroperitoneal depots (figure 7).  
In summary, it was found that visceral depots have elevated IR expression 
compared to subcutaneous depots, which supports previous findings by Lefebvre et al. 
(Lefebvre, Laville et al. 1998), but contradicts a study by Bolinder et al. (Bolinder, Kager 
et al. 1983), which concluded that there was no significant difference between numbers 
of receptors in omental and subcutaneous AT. Further studies regarding the expression of 
IR in wild type mice have been discussed extensively in chapter 1. 
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Figure 6. mRNA expression of receptor genes in WAT  in three month old mice. Real-
time PCR analysis of GHR (A), IGFIR (B), IR (C). Shown are means ± SEM, n=13 for 
Epi, n=12 for Mes, n=7 for Retro, n=14 for Subq. Means that share a common letter are 
not significantly different, p>0.05. Modified and used with permission (Miles 2009) 
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Figure 7. mRNA expression of receptor genes in WAT  in nine month old mice. Real-
time PCR analysis of GHR (A), IGFIR (B), IR (C), and IR-B (D). Shown are means ± 
SEM, n=5 for Epi, n=6 for Mes, n=5 for Retro, n=7 for Subq. Means that share a 
common letter are not significantly different, p>0.05. Modified and used with permission 
(Miles 2009) 
 
2.5.: Aims and hypotheses 
 This thesis builds on research completed by D. Bailey Miles detailed in the Ohio 
University Honors Tutorial College Thesis, “Depot specific differences in GH, IGF-1 and 
insulin receptors in adipose tissue”. This work will further develop the knowledge base 
regarding depot-specific differences in wild type mice by elucidating which cellular 
components of WAT are primarily responsible for the expression of GHR, IGF-1R, and 
IR. Furthermore, this project will be the first to directly compare the expression of these 
receptors in the adipose depots of GHA mice. Based on previous studies regarding depot-
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specific differences and the effects of the ablation of these receptors, I originally 
proposed these aims and hypotheses:  
Aims 
1.) To determine the relative RNA expression of GHR, IGF-1R, and IR in the 
adipocyte and SVF portions of WT mouse subcutaneous, epididymal, 
retroperitoneal, and mesenteric WAT depots. 
2.) To determine the difference in RNA expression of the above receptors in the 
whole WAT depots of GHA mice compared to WT mice. 
Hypotheses 
1) Aim 1 hypothesis: WT mice will exhibit the highest expression of GHR in 
SVF (in visceral depots only due to elevated macrophage populations), but the 
highest expression of IGF-1R and IR in adipocytes (due to the importance of 
both these receptors in insulin signaling in adipocytes). Furthermore, due to 
increased populations of immune cells present in visceral depots, GHR 
expression will be highest in these depots compared to subcutaneous depots. 
2) Aim 2 hypothesis: The GHA mice will have elevated expression of IGF-1R 
and IR in the visceral adipose depots compared to the subcutaneous depots. 
Contrary conclusions have been drawn regarding the importance of GHR-
mediated GH signaling in the subcutaneous depot, so it is difficult to propose 
how the RNA expression will be affected in this depot. However, most of the 
evidence derived from mouse models of reduced GH signaling seems to 
suggest that GHR-mediated signaling is important in this depot; therefore, I 
  44 
hypothesize that GHR mRNA will be elevated in subcutaneous WAT 
compared to the other depots. 
Note that Aim 1 was modified due to problematic isolation of RNA from 
adipocytes;receptor expression was examined in RNA from SVF of one group of WT 
mice (Aim 1 mice) and in RNA from whole WAT depots of a second group of WT mice 
(Aim 2 WT controls). 
2.6.: Aim 2 preliminary data for GHA mice  
 There are preliminary data available for the GHA and wild type control mice used 
in Aim 2 that were generated by others in the laboratory.   I was not involved in that data 
collection,  however, I want to show these data here.  Prior to sacrificing the WT and 
GHA mice utilized in Aim 2, body composition analyses and glucose and insulin 
tolerance tests (GTTs & ITTs) were performed.  At dissection, the body lengths of the 
mice were recorded as well as the weights of WAT depots and several other tissues. 
These data are shown in figures 8, 9, and 10 below and overall are in accordance with 
previous studies with these mice (Coschigano, Holland et al. 2003; Berryman, List et al. 
2004). 
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Figure 8. Body composition data for 12 month-old male GHA and WT mice. Data are 
reported as (A) mass in grams and as (B) percentage of body mass. Shown are means ± 
SEM, n=8 for each group. Means designated with an asterisk are significantly different, 
p<0.05. 
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Figure 9. ITT (A) and GTT (B) for 12 month-old male GHA and WT mice. Shown are 
means ± SEM, n=8 for each group. Means designated with an asterisk are significantly 
different, p<0.05. 
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Figure 10. WAT depot weights (A), WAT depot weights normalized to body weight (B), 
organ weights (C), and lengths (D) of 12 month-old male GHA and WT mice. Shown are 
means ± SEM, n=8 for each group. Means designated with an asterisk are significantly 
different, p<0.05. 
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Figure 11. Serum insulin concentration of 12 month-old male GHA and WT mice. 
Shown are means ± SEM, n=8 for each group.  
 
The body composition analyses, ITTs and GTTs, and analyses of serum insulin 
and tissue weights provide important background information that emphasizes the 
differences in GHA and WT mice. Body composition analyses showed that the GHA and 
WT mice have a significant difference in weights and percentages of all body 
components (fat, lean, fluid); however, their total body weights showed no significant 
difference (figure 8). This indicates that while the two groups of mice have similar body 
weights, GHA mice have a greater percentage of fat compared to lean mass, while WT 
mice have a greater percentage of lean mass compared to fat. This agrees with the body 
composition analysis of GHA mice reported previously (Berryman, Lubbers et al. 2014).  
That is, male GHA mice tend to have significantly smaller body weights compared to 
littermate controls until approximately one year of age when the body weights are no 
longer significantly different.  
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 Data obtained from ITTs and GTTs revealed that this cohort of GHA mice exhibit 
a stronger response to insulin and  were thus more insulin sensitive at the 45, 60, and 90 
min time points compared to WT mice (figure 9A), but were less glucose tolerant at the 
15 and 30 min time points (figure 9B).  Previously, GTT data collected from 72 week-old 
GHA and WT mice showed no significant difference in area under the curve in the two 
groups (Berryman, Lubbers et al. 2014). A statistical comparison of serum insulin levels 
(figure 11) in the two groups showed no significant difference. As a previous study using 
16- to 18-week-old male mice showed GHA mice have significantly less serum insulin 
compared to controls, this most likely indicates an age-related difference (Yakar, Setser 
et al. 2004). Additionally, even when GHA mice are kept on a high-fat diet, they do not 
develop hyperinsulinemia (Yang, Householder et al. 2015). 
 The analysis of tissue weights obtained from the dissection of the GHA and WT 
mice tissues showed that GHA mice have significantly smaller liver, kidney, and soleus 
muscle, but increased brown adipose tissue (BAT) mass (figure 10C). Before 
normalization to body weight, there were no significant differences in WAT depot 
masses in the two groups (figure 10A), but after normalization, GHA showed relative 
enlargement of the subcutaneous depot (figure 10B), which correlates with previous 
studies showing enlargement of this depot in these mice (Berryman, List et al. 2004). 
These data, combined with the body composition data, provide further evidence that 
while GHA mice have less lean tissue mass, their WAT makes up a larger percent of 
body weight than in WT mice. 
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CHAPTER 3: MATERIALS AND METHODS 
3.1: Animals 
 Two separate cohorts of male, 12 month-old mice of the C57BL/6J genetic 
background were used for the specific aims of this thesis. For Aim 1, only C57BL/6J 
wild type mice were used (n=8).  For Aim 2, WAT depots were obtained from GHA mice 
produced as previously described (Chen, White et al. 1991). In brief, to create the mouse 
line, microinjection was utilized to insert a bovine GH minigene containing an amino 
acid substitution in the third alpha helix into the germline; this results in the replacement 
of glycine 119 by lysine. Mice were genotyped using PCR utilizing DNA isolated from a 
tail, as previously described (Berryman, List et al. 2004). Eight mice were used from each 
group, wild type (WT) and GHA. For both aims, mice were caged two to four per cage in 
rooms with controlled light cycles (12 hours light and dark), with temperature of 22 ± 
2ºC and were provided food and water ad libitum. Preliminary data including body 
composition, tissue weights, glucose and insulin tolerance tests, and serum insulin levels 
for this cohort of GHA and WT mice are shown in section 2.6 of this thesis. All 
procedures were approved by the Ohio University Institutional Care and Utilization 
Committee. 
3.2: Body composition analysis 
 The day before dissection, a quantitative NMR machine (Minispec, Bruker 
Optics, Billerica, MA or Echo MRI whole body composition analyzer; Echo Medical 
Systems, Houston, TX) was used to analyze body composition of mice used in Aim 1 as 
previously described (Palmer, et al. 2009). 
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3.3: Tissue collection  
  For Aims 1 & 2, the mice were anesthetized with CO2, bled (blood was collected 
via retro-orbital bleed) and euthanized via cervical dislocation. Blood samples were 
maintained at room temperature for 20 minutes, then centrifuged at 4000g for 10 minutes 
at 4 ºC to collect the serum.  Serum samples were stored at -80ºC. Subcutaneous, 
epididymal, retroperitoneal, and mesenteric adipose depots were dissected and weighed. 
For Aim 1, the WT WAT depots were placed in 50 mL conical tubes containing 15 mL 
Hank’s Balanced Salt Solution (HBSS) (HyClone, HBSS/Modified, no calcium, 
magnesium) kept on ice for further processing as described in the subsequent section.  
For Aim 2, the GHA adipose depots were flash frozen in liquid nitrogen and stored at -80 
ºC until further processing.  
3.4: SVF isolation (Aim 1)  
Tubes with adipose depots in Hank’s HBSS were inverted several times to wash 
the tissues. The tissues and HBSS were poured into a petri dish where the tissues were 
minced into small pieces using dissecting scissors. The minced tissue was transferred to 
conical tubes on ice. A solution of HBSS with 2 mg/mL collagenase (Sigma Life Science, 
Collagenase from Clostridium histolyticum, > 125 CDU/mg solid, Lot # SLBL6040V) 
was prepared and added to each depot in an equal volume-to-volume ratio. The tubes 
were removed from ice and placed in a shaking incubator set at 37º C and 150 rpm. The 
tissues were allowed to digest approximately 30 minutes. The tubes were removed and 
placed on ice immediately once all the tissue appeared to be digested.  
 Following complete digestion of tissues, floating adipocytes were skimmed from 
the surface using a plastic pipette and transferred to 1.5 mL microcentrifuge tubes on ice. 
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The HBSS solution in the tubes contain the SVF cells. This solution was poured through 
a 100 µm cell strainer (Fisher Scientific, Falcon, catalog #08-771-19) into a clean 50 mL 
conical tube. The conical tubes were then centrifuged at 4º C, at approximately 4,500 x g 
for 10 minutes to pellet the SVF cells at the bottom. While waiting for centrifugation of 
the SVF, Trizol reagent (Thermo Fisher Scientific, Life Technologies) was added to the 
adipocytes in a 3:1 (Trizol:cells) ratio. The tubes were then vortexed briefly and frozen at 
-80º C. 
 The tubes containing the SVF were removed from the centrifuge. The supernatant 
was decanted, being careful not to disturb the pellet of cells collected in the bottom. The 
tubes were then tapped gently to dislodge the pellet and resuspend the cells. The small 
amount of supernatant remaining (along with the suspended cells) was transferred to 1.5 
mL microcentrifuge tubes. To remove any excess cells attached to the bottom of the 
conical tube, 600 µL of Trizol reagent was added to the conical tubes, followed by brief 
pipetting up and down. This solution was added to the microcentrifuge tubes containing 
the stromal vascular cells. Finally, the tubes were vortexed briefly and then frozen at -80º 
C. For more information on the SVF isolation protocol used, see Appendix A. 
3.5: Whole tissue preparation (Aim 2) 
To prepare whole tissue for RNA isolation, collection and homogenization steps 
were performed as follows.  Approximately 150 mg sections of frozen GHA mouse WAT 
from subcutaneous, epididymal, retroperitoneal, and mesenteric depots was collected and 
submerged in 200 µL Trizol reagent in 1.5 mL microcentrifuge tubes (Life Technologies, 
Fisher Scientific) to prepare them for RNA isolation.  
  53 
3.6. RNA isolation 
 To prevent contamination by RNases, the entire work area, gloves, and all utensils 
were sprayed consistently with RNase AWAY (Molecular BioProducts, Fisher 
Scientific). Isolating the RNA from the adipocytes and SVF cells (Aim 1) as well as the 
tissue samples (Aim 2) was done in a similar manner.  For Aim 1, the frozen adipocytes 
and SVF in Trizol was utilized. For Aim 2, 150 mg portions of the frozen GHA AT were 
used for RNA isolation.  
For Aim 2, the tissues in microcentrifuge tubes with 200 µL Trizol (as described 
in the previous section) were homogenized using a handheld homogenizer (Kontes, Pellet 
Pestle Motor) with detachable tips. From this point, the RNA isolation procedure was the 
same for Aims 1 and 2 with the exception that for Aim 1 samples were first thawed 
before proceeding.  
Tubes were vortexed at maximum speed for about 5 min, and then were 
centrifuged for 5 min at 17,000 x g at 4º C. These settings were maintained throughout 
the procedure. Following centrifugation, a 1 mL syringe with a 22G x 1 ½ (0.7 mm x 40 
mm) needle was used to remove the Trizol layer, being careful to avoid touching the 
clear/white lipid layer floating on top (this lipid layer is present in the whole tissue 
samples used in Aim 2, as well as the adipocyte samples from Aim 1, but not in the SVF 
samples). This layer was then transferred to a new tube. Two hundred microliters of 
chloroform was added, the samples were vortexed, and finally centrifuged for 15 min. 
Using a 200 µL micropipette, the clear aqueous layer on top of the samples was removed, 
being careful not to touch the protein layer (white and cloudy) or the Trizol layer. It was 
then transferred to a new tube. To the new tubes, 500 µL isopropanol was added, which 
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was followed by vortexing. The samples were kept at room temperature for 10 min, 
followed by 10 min centrifugation. The supernatant was then poured off into a new tube, 
being careful not to pour out the pellet. Ice cold 70% ethanol was then used to complete a 
series of three washes. During each wash, 1 mL ethanol was pipetted into the tubes, 
followed by a brief vortex, then a 15 min centrifugation. The supernatant was again 
poured off. This process was completed twice more. Following this, the supernatant was 
poured off a final time, and the tubes were tapped gently on an RNase AWAY-sprayed 
paper towel to remove excess ethanol. The tubes were then allowed to dry upside-down 
for at least one hour. Finally, the RNA pellet was dissolved in 25 µL molecular grade 
water (DNAase-, RNAase, and proteinase-free water, Sigma-Aldrich) by gently pipetting 
up and down. RNA quantity and quality were analyzed using the Nanodrop 2000 UV/Vis 
spectrophotometer (Thermo Fisher Scientific). RNA samples utilized for cDNA synthesis 
had minimum concentration of 100 ng/µL and 260/280 and 260/230 ratios of 
approximately 1.80 to 2.00. For more details on the RNA isolation protocol used, see 
Appendix B. 
3.7: Synthesis of cDNA from isolated RNA 
RNA isolated from SVF cells, adipocytes, and whole AT was converted to cDNA 
using the Thermo Scientific Maxima First Strand cDNA Synthesis Kit for RT-qPCR. In 
brief, 4 µL 5X Reaction Mix and 2 µL Maxima enzyme were combined with a volume of 
RNA normalized to concentration for each sample. Components were mixed in 
microcentrifuge tubes on ice, followed by the addition of molecular grade water to bring 
the total volume to 25 µL. The tubes were incubated for 10 min at 25ºC, then for 15 min 
at 50ºC. The reaction was then terminated by heating at 85ºC for 5 min. 
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3.8: qPCR analysis  
qPCR was performed using the Thermo Scientific Maxima SYBR 
Green/Fluorescein qPCR Master Mix (2x) kit. The Bio-Rad iCycler iQ Real Time PCR 
Detection System (Bio-Rad Laboratories, Hercules, CA) was utilized to run the reaction. 
In brief, the reaction master mix was first prepared by combining 12.5 µL of the Maxima 
SYBR Green/Fluorescein qPCR Master Mix (2X), 0.3 µM of both the forward and 
reverse primers, and nuclease-free water to bring the reaction volume to 25 µL. These 
components were mixed thoroughly then added to the PCR plate wells, followed by 5 µL 
of 1:15 diluted template cDNA. The thermal cycling conditions were as follows: initial 
denaturation (50º C, 2 min) and then 40 cycles of denaturation (95ºC, 15 s), annealing 
(60ºC, 30 s), and extension (72ºC, 30 s). Primers were utilized to measure the expression 
of GHR, IGF-1R, and IR, as well as the reference genes eukaryotic translation elongation 
factor 2 (EEF2) and beta-2-microglobulin (B2M). For Aim 1, primers for F4/80 and 
adiponectin (ADIPOQ) were used to ensure adequate separation of the SVF and 
adipocyte portions. All qPCR primers were purchased from Sigma-Aldrich. qPCR primer 
sequences are given in table 6. Threshold count (Ct) values were obtained from the 
iCycler instrument and converted to relative quantities using the equation 2(minimum Ct value 
of all samples)-(Ct value of specific sample). The normalization factor was then calculated based on the 
geometric mean of the housekeeping genes. 
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Table 6. Sequences of qPCR primers used. 
primer Sequence (5’ to 3’) 
GHR 
Forward GCCTGGGGACAAGTTCTTCTGGA 
Reverse TGCAGCTTGTCGTTGGCTTTCCC 
 
IGF-1R 
Forward AGAACCGAATCATCATAACG 
Reverse TTTTAAATGGTGCCTCCTTG 
 
IR 
Forward CAAACAGATGCCACTAATCC 
Reverse CTTTGAGACAATAATCCAGCTC 
 
B2M 
Forward CTGGTCTTTCTATATCCTGGCT 
Reverse CATGTCTCGATCCCAGTAGAC 
 
EEF2 
Forward CGGTACTTTGATCCGGCCA 
Reverse TGATGGCGTCGAACACCTTG 
 
F4/80 
Forward  CTTTGGCTATGGGCTTCCAGTC 
Reverse GCAAGGAGGACAGAGTTTATCGTG 
ADIPOQ 
Forward CTCTCCTGTTCCTCTTAATCCT 
Reverse ACCAAGAAGACCTGCATCTC 
 
3.9: ELISA quantification of plasma insulin (Aim 1) 
 Plasma insulin in 12-month old male WT mouse plasma was quantified in 
duplicate using an Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem Inc., 
Downers Grove, IL, catalog #90082) according to the manufacturer’s instructions. 
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3.10: Statistical measures 
 All data were reported as mean ± standard error of the mean (SEM). For Aim 1, 
significant differences in receptor RNA expression among depots and significant 
differences in receptor expression were determined using a one-way ANOVA followed 
by a Tukey’s post-hoc test. This statistical test was also used to determine significant 
differences in adipose tissue depot mass and body composition. For Aim 2, significant 
differences in expression between GHA and WT were determined using a two-tailed t-
test, and where necessary, the Mann-Whitney U test. Statistical analyses were performed 
using RStudio (Boston, MA). Significant differences were designated by a p value < 
0.05. 
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CHAPTER 4: RESULTS 
4.1: Aim 1  
 The results of the body composition analysis of the 8 male 12-month old mice are 
shown in figure 12.  As expected, the mice possessed more lean mass than fat and fluid 
mass.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Body composition data for 12 month-old male WT mice. Data are reported as 
(A) mass in grams and as (B) percentage of body mass. Shown are means ± SEM, n=8 
for each group. Means that share a common letter are not significantly different, p>0.05. 
 
0	  
10	  
20	  
30	  
40	  
50	  
Fat	   Lean	   Fluid	  
M
as
s	  (
g)
	  
a	  
b	  
	  a	  
0	  
10	  
20	  
30	  
40	  
50	  
60	  
70	  
80	  
Fat	   Lean	   Fluid	  
Pe
rc
en
t	  B
od
y	  
M
as
s	  
	  	  a	  
	  	  b	  
	  	  	  a	  
A	  
B	  
  59 
 Analysis of WAT depot mass showed that the epididymal depot was significantly 
larger than the subcutaneous, retroperitoneal, and mesenteric depots (figure 13). 
 
  
Figure 13. WAT depot weights of 12 month-old male WT mice. Shown are means ± 
SEM, n=8 for each group. Means that share a common letter are not significantly 
different, p>0.05. 
 
 While the initial Aim was to compare receptor expression between adipocyte and 
SVF portions, despite many attempts to isolate quality RNA from adipocyte fractions, 
RNA sample concentrations remained poor in three out of four of the depots (table 7). 
Furthermore, many adipocyte samples possessed 260:280 and 260:230 ratios below the 
cutoff of 1.80. This could be attributed  to the high lipid content and fragility of 
adipocytes, two traits which makes isolating high quality RNA difficult. However, high 
quality RNA was isolated from the SVF portions. For this reason, a comparison of SVF 
and whole WAT receptor expression was performed instead using whole WAT from the 
WT cohort from Aim 2.  
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Table 7. A comparison of SVF and adipocyte RNA concentrations. 
Depot Adipocyte RNA 
concentration 
SVF RNA 	  
concentration 
Subcutaneous	   48.5±15.1	   209.3±12.5	  
Epididymal	   273.6±35.1	   426.4±51.6	  
Retroperitoneal	   41.7±11.1	   177.3±38.1	  
Mesenteric	   37.5±14.7	   247.3±29.1	  
 
A comparison of the body composition, WAT weight data, and serum insulin 
levels determined by ELISA indicate that the group of 12 month-old male WT mice used 
in this Aim show no significant differences in these parameters from the group of 12 
month-old male WT mice used in Aim 2 (these data for mice used in Aim 2 are shown in 
figures 8, 10, and 11, comparison data shown in table 8).  
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Table 8. Comparison of metabolic parameters of 12 month-old male WT. 
 Aim 1 WT Aim 2 WT P value 
Fat (g) 7.7±1.9 8.7±1.0 0.35 
Lean (g) 28.0±0.9 26.0±0.7 0.09 
Fluid (g) 6.5±0.23 6.1± 0.2 0.22 
Fat (% of body 
weight) 
18.0±3.9 21.0±1.8 0.21 
Lean (% of body 
weight) 
69.0±3.4 65.3±1.8 0.35 
Fluid (% of body 
weight) 
16.0±0.4 15.0±0.1 0.08 
Subcutaneous (g) 0.71±0.2 1.0±0.3 0.88 
Epididymal (g) 1.4±0.2 1.6±0.2 0.52 
Retroperitoneal (g) 0.33±0.1 0.42±0.1 0.28 
Mesenteric (g) 0.59±0.2 0.53±0.1 0.76 
Serum insulin 
(ng/mL) 
1.3±0.7 2.1±0.4 0.25 
 
 This group of WT mice used in this aim had a mean serum insulin level 
(determined by ELISA) of 1.3±0.7 ng/ml. Although the mice showed a large variation in 
serum insulin, the serum insulin level showed a strong positive correlation with WAT 
mass as a percentage of body weight (R2= 0.850) (figure 14). As it was not possible to do 
a direct comparison of expression in WAT and SVF from the same mice (due to the large 
amount of WAT necessary for SVF isolation), this comparison ensured that the two 
groups of mice utilized were phenotypically similar. 
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Figure 14. Serum insulin and adipose tissue mass as a percentage of body weight in 12 
month-old WT mice. 
 
 To ensure adequate separation of adipocytes from SVF, an attempt was made to 
compare RNA expression of ADIPOQ and F4/80 in these samples, which are considered 
to be expressed mainly in adipocytes and the SVF respectively.   However, too few 
adipocyte samples possessed sufficient RNA concentration or purity to provide an 
appropriate comparison of RNA expression of these genes in adipocyte and SVF 
samples.  
 The qPCR layout utilized allowed for the comparison of GHR, IGF-1R, and IR 
RNA among depots (figure 15) and for the direct comparison of RNA expression levels 
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expression in the SVF of the epididymal depot trended toward being greater than the 
expression in the SVF of the mesenteric depot (P=0.0834)(figure 15). Note that n of 
qPCR analyses do not match n values of mice, as in some cases it was necessary to 
0	  
5	  
10	  
15	  
20	  
25	  
30	  
35	  
40	  
45	  
0	   1	   2	   3	   4	   5	   6	  
Fa
t	  a
s	  p
er
ce
nt
	  b
od
y	  
w
ei
gh
t	  
Serum	  insulin	  (ng/ml)	  
R2	  =	  0.850	  
  63 
eliminate samples with outlying reference gene RNA expression levels in order to meet 
reference gene stability requirements. Additional variation in the n of the IGF-1R 
analyses is due to the IGF-1R RNA being undetectable in some samples. 
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Figure 15. RNA expression of GHR (A), IGF-1R (B), and IR (C) in SVF of WATdepots 
of 12 month-old male WT mice. Real-time PCR analysis of GHR (n=6-7), IGF-1R (n=3-
5), and IR (n=4-6). Shown are means ± SEM.  
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 The comparison of levels of GHR, IGF-1R, and IR in each depot showed no 
significant differences (figures 16 and 17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. RNA expression of GHR, IGF-1R, and IR in SVF of subcutaneous (A), 
epididymal (B), retroperitoneal (C), and mesenteric (D) WAT depots of 12 month-old 
male WT mice. Real-time PCR analysis of GHR (n=6-7), IGF-1R (n=3-5), and IR (n=4-
6)). Shown are means ± SEM. 
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Figure 17. RNA expression of GHRIGF-1R, and IR of whole subcutaneous (A), 
epididymal (B), retroperitoneal (C), and mesenteric (D) WAT depots of 12 month-old 
male WT mice. Real-time PCR analysis of GHR (n=5-7), IGF-1R (5-7), and IR (n=5-7). 
Shown are means ± SEM. 
 
 
4.2: Aim 2 
 The background data (including data for body composition, WAT depot weight, 
plasma insulin, and GTT and ITT) for the groups of GHA and WT mice used in Aim 2 
0	  
1	  
2	  
3	  
4	  
5	  
6	  
GHR	   IGF1R	   IR	  
0	  
1	  
2	  
3	  
4	  
5	  
6	  
GHR	   IGF1R	   IR	  
0	  
1	  
2	  
3	  
4	  
5	  
6	  
GHR	   IGF1R	   IR	  
0	  
1	  
2	  
3	  
4	  
5	  
6	  
GHR	   IGF1R	   IR	  
A	  
D
B	  
C	  
  67 
are detailed in section 2.6. The results of the qPCR analysis of GHR, IGF-1R, and IR in 
subcutaneous, epididymal, retroperitoneal, and mesenteric WAT depots indicated that 
GHR RNA is expressed significantly more in mesenteric WAT of GHA mice than in WT 
mice. While this was the only significant difference observed when receptor RNA 
expression was compared between genotypes, IGF-1R in the subcutaneous depot of GHA 
mice was trending toward being significantly higher than in WT mice (p = 0.096), as was 
the case with IR in the mesenteric depot (p = 0.074) (figure 18).  
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Figure 18. RNA expression of receptors in subcutaneous (A), epididymal (B), 
retroperitoneal (C), and mesenteric (D) WAT depots of 12 month-old male GHA and WT 
mice. Real-time PCR analysis of GHR (n=6-8), IGF-1R (n=5-8), and IR (n=6-8), 
comparison of expression in GHA and WT WAT depots. Shown are means ± SEM. 
Significant differences in GHA and WT receptor expression are designated with an 
asterisk, p<0.05. 
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CHAPTER 5: DISCUSSION AND CONCLUSIONS 
 Differential hormone receptor expression may contribute to the many depot 
differences that have been reported in WAT.  Therefore, the purpose of this study was to 
better understand the expression of GH, IGF-1, and insulin receptors in various WAT 
depots.  In Aim 1, we attempted to compare the expression in the SVF versus adipocytes 
in wild-type animals; however, due to quality issues with the RNA isolated from 
adipocytes, this Aim instead became a comparison of receptor expression among the 
various depots in the SVF only.  In Aim 2, we hoped to help explain the well-documented 
differences in depot expansion in GHA transgenic mice. These mice show preferential 
weight gain in the subcutaneous depots.  Below summarizes the results, discusses 
limitations and describes future studies based on my findings.    
5.1: Aim 1  
 While no significant differences were found in the comparison of the RNA 
expression of GHR, IGF-1R, and IR in whole WAT of WT mice, a trend toward 
significance was observed in the SVF expression of IR. More specifically, IR tended to 
be more highly expressed in the SVF of the epididymal depot than in the SVF of the 
mesenteric depot. As IR is expressed in several types of SVF cells, including monocytes, 
macrophages, and neutrophils (Liang, Han et al. 2007; Mauer, Chaurasia et al. 2010); 
differing cell populations in these depots could account for differences in IR expression. 
Contrary to this hypothesis are results from a study in younger WT mice (5 month) which 
examined immune cell populations and found no significant differences in immune cell 
populations among depots, or in the total number of SVF cells per gram of tissue 
(Harshman 2012).  However, the mice used in this thesis were much older. We know 
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based on many longitudinal measures of body composition over lifespan in mice of the 
C57Bl/6J strain (Berryman, List et al. 2004; List, Palmer et al. 2009; Palmer, Chung et al. 
2009; Berryman, List et al. 2010) that adiposity continues to significantly increase with 
advancing age in mice from this strain.  Therefore, it is not unexpected that age-related 
changes in expression of hormone levels will shift with advancing age. Furthermore, 
evidence for age-related changes in SVF, specifically in the epididymal depot, is 
provided by a study examining SVF populations of old (18-22 month) and young 
C57BL/6 mice (3-4 month) (Lumeng, Liu et al. 2011). This study found an increase in 
the total number of SVF cells per epididymal depot (that persisted after normalization for 
the weight of the depot), as well as a two-fold increase in lymphocytes in the older mice 
in this depot (Lumeng, Liu et al. 2011).  Thus, the Lumeng et al. study provides evidence 
that dramatic changes in the composition of SVF occur as mice age. As SVF populations 
change over time, it is likely that the certain SVF cell populations possessing these 
receptors are altered over time as well. 
In addition to the comparison of receptor RNA expression in SVF, a comparison 
of expression in whole WAT was made; however, no significant differences in the 
expression among depots were observed. These results differ from  previous receptor 
RNA expression data in whole WAT in 3 and 9 month-old mice  (Miles 2009). In that 
previous study with 9 month-old mice, RNA expression of GHR in whole tissue from the 
mesenteric and epididymal depots did not differ significantly, but in 3 month-old mice, 
GHR was expressed more highly in the epididymal depot compared to the mesenteric and 
subcutaneous depots  Furthermore, in the 9 month-old mice, IGF-IR was expressed more 
highly in the mesenteric depot compared to the retroperitoneal depot, while IR was 
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expressed more highly in the mesenteric depot compared to the retroperitoneal and 
subcutaneous depots. As I did not detect any significant differences in receptor 
expression among depots in whole WAT of 12 month-old mice, this could suggest that 
WAT depots’ functional differences are a result of proteins besides GHR, IGF-1R, and 
IR. 
5.2: Aim 2 
 Overall, qPCR analysis of receptor expression between the genotypes 
revealed few significant differences.  In fact, the only significant difference was the 
higher expression of GHR in the mesenteric depot of the 12 month-old male GHA mice 
compared to the WT mice. Recall, that mesenteric is the only true visceral depot studied 
in this thesis; thus, it may respond differently to the reduction in GH-induced signaling. 
This difference could suggest that, in GHA mice, the competition for GHR binding by the 
GHA molecule functions to upregulate GHR expression in this WAT depot. Contrary to 
this hypothesis, a previous study has shown that addition of pegvisomant, the GH 
antagonist, has no effect on GHR expression when administered to a human hepatoma 
cell line (Deladoey, Gex et al. 2002). However, it is important to note that this study 
examined the in vitro effects of the GH antagonist only, allowing for the possibility that it 
may behave differently in vivo. Furthermore, the lack of differences in GHR RNA 
expression in all the remaining depots in this thesis suggest that this explanation is, at 
minimum, tissue dependent.  GHR expression has been shown to be regulated differently 
in different tissues.  More specifically, GHR mRNA expression in the kidney of GHA 
mice is reduced compared to non-transgenic littermates, while it is elevated in the liver 
(Chen, Chen et al. 1997), indicating that different tissues respond differently to GHA. 
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An alternative explanation for this result could lie in the differing SVF cell 
populations of WAT depots. In humans, visceral depots are known to have higher 
numbers of immune cells, more crown-like structures and secrete more inflammatory 
cytokines (Fried, Bunkin et al. 1998; Milan, Granzotto et al. 2002; Altintas, Azad et al. 
2011).  In mice, the mesenteric depot is known to express high levels of monocyte 
chemoattractant protein-1 (MCP-1), a molecule responsible for the activation and 
migration of WAT macrophages (Yu, Kim et al. 2006). Thus, the mesenteric depot is 
likely to be more responsive to the inflammatory state.  WAT tissue macrophages, in 
addition to adipocytes, express the GHR (Lu, Kumar et al. 2010). It is known that 5 
month-old WT mice show no significant differences in WAT macrophage numbers in the 
subcutaneous, epididymal, and mesenteric depots (Harshman 2012). While WAT 
macrophage populations in GHA mice have not been determined, nor how populations 
differ between GHA WAT depots, one explanation for the change in GHR expression in 
this depot is that GHR-expressing  SVF cells are more prevalent in this depot in GHA 
mice.  
IR in the mesenteric depot, while not quite reaching significance, was expressed 
more in GHA than in WT mice. This trend could also be attributed to excess immune 
cells, such as monocytes, macrophages, and neutrophils in the mesenteric depot, as it is 
known that these cells undergo IR-induced signaling (Liang, Han et al. 2007; Mauer, 
Chaurasia et al. 2010). Showing a similar pattern to GHR and IR in the mesenteric depot, 
IGF-1R expression in the subcutaneous depot approached significance, with GHA mice 
expressing the receptor more strongly than the WT mice. Male GHA mice have been 
shown to have decreased expression of IGF-1 compared to WT controls (Coschigano, 
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Holland et al. 2003); thus, the lack of IGF-1 in GHA mice could be upregulating the IGF-
1R in this depot. In addition to the differences in receptor RNA observed between the 
genotypes in some depots, the depots and receptors that do not show expression 
differences reveal important characteristics of these mice as well. The lack of significant 
differences observed might underlie the fact that GHA mice, with reduced levels of GH-
induced signaling, do not possess extended lifespans or significant improvements in 
glucose metabolism as is observed in GHR-/- mice that exhibit ablation of the GHR 
(Berryman, Lubbers et al. 2014). Lending support to this hypothesis is the fact that in 
none of the depots did the reduction in GH-induced intracellular signaling in the GHA 
mice result in significantly altered IR expression levels. This lack of change in IR is 
supported by work in which it was shown that GHA mice do not exhibit the change in 
insulin levels as seen in GHR-/- mice (Coschigano, Holland et al. 2003). As reduction in 
insulin-induced signaling is linked to lifespan extension (Bluher, Kahn et al. 2003), this 
important difference in GHA and GHR-/- mice may explain why GHA mice do not 
possess the lifespan extension seen in GHR-/- mice. Considering these points, the data 
acquired from my work suggest that GHA mice may have metabolic characteristics more 
similar to WT mice than to GHR-/- and thus the results of inhibition of GH-induced 
signaling are not adequate to result in lifespan extension and improvements in glucose 
metabolism in later life.  
5.3: Limitations 
For Aim 1, it would be of value to verify that the SVF isolation procedure was 
efficient at separating the SVF cells from the adipocytes.  To do this, the expression of 
markers of adipocytes versus the SVF could be performed.  An attempt was made to 
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gather expression data of several adipocyte- and SVF-specific genes, including ADIPOQ 
(an adipocyte marker) and F4/80 (a macrophage marker) for purposes of ensuring 
adequate separation of the SVF and adipocyte portions. Unfortunately, the number of 
adipocyte samples of adequate concentration and quality did not allow for a direct 
comparison of the expression level of ADIPOQ and F4/80 in SVF and adipocytes. 
Although the RNA expression level of these genes was highly variable in the SVF 
portions, a direct comparison of the expression in corresponding adipocyte and SVF 
samples would have provided  clearer, more convincing results.  
The qPCR analysis of IGF-1R was particularly problematic, as the IGF-1R RNA 
was undetected in many samples.  As might be expected, this resulted in small n values 
and large variation in the RNA expression levels of that gene.  As a result, the data 
generated with IGF-1R, in particular, are questionable. It is not clear why this particular 
primer set/gene resulted in greater problems as the primer set has been used successfully 
by others in our laboratory; however, many primer sets can be used with greater success 
in certain tissues and cells compared to others. Thus, testing of alternative primer sets for 
IGF-1R should be designed and tested. 
As the SVF isolation process required such a large amount of WAT, it was 
unfortunately not possible to perform a direct comparison of SVF and whole WAT from 
the control mice. Directly comparing receptor expression in the SVF versus whole tissue 
would have been valuable in this study although a comparison of SVF to adipocytes, as 
originally planned, would have been more useful.   
Although the control mice were of the same genetic background and possessed no 
significant differences in several parameters, it is important to recognize that there are 
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differences among individual mice, even in those of the same age and genetic 
background.  Therefore, it is suggested to interpret this preliminary data as a first step in 
examining receptor expression in SVF and adipocytes.  
5.4: Future studies 
As this thesis focused on a comparison of SVF and whole WAT depots in two 
separate but similar groups of mice, further studies could attempt to optimize the RNA 
isolation process from adipocytes, or optimize the SVF isolation process to allow for use 
of less WAT, thus allowing for a direct comparison of whole tissue and SVF. Also, as 
this thesis examined the RNA expression of receptors and found limited significant 
differences, it is possible that the same comparison when made at the protein level could 
produce different results.  While it has not been determined how closely GHR, IGF-R, 
and IR RNA expression correlates with the expression of their corresponding proteins, 
some studies provide evidence that many genes can have largely varying RNA and 
protein levels (Tian, Stepaniants et al. 2004; Lundberg, Fagerberg et al. 2010).This 
comparison would only be feasible for IGF-1R and IR; this would be challenging for 
GHR as antibodies to mouse GHR are not commercially available. 
Further studies could examine how SVF cell populations differ among GHA and 
WT WAT depots. Using antibodies specific to SVF cell surface markers, fluorescence 
activated cell sorting (FACS) could be used to count and sort SVF cell populations. This 
method has been used effectively in 5 month-old WT and bovine growth hormone (bGH) 
transgenic mice to reveal differences in SVF cell populations in the two genotypes and 
has shown significant depot and genotype effects (Harshman 2012).  Thus, the SVF 
composition likely varies in the GHA line as well. This method, applied to GHA mice, 
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could give important insight into why GHA mice show differences in receptor expression 
in the mesenteric depot.  
Age is another variable that is likely important.  The GHA and WT mice have no 
difference in lifespan (Coschigano, Holland et al. 2003).However, there is evidence that 
many of the variables tested longitudinally in these mice change with advancing age.  For 
example, leptin and glucose tolerance increase with advancing age in GHA male mice 
relative to controls (Berryman, Lubbers et al. 2014) Therefore, it is likely that the age of 
the mice will impact the tissue results presented in Aim 2.  In this study, we used 1 year 
old mice.  One year old male GHA mice are severely obese by this age but have no major 
changes yet to glucose homeostasis (Berryman, Lubbers et al. 2014).   
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APPENDIX A: SVF ISOLATION 
Protocol adapted from (Harshman 2012) 
 
Materials: 
• Hank’s Balanced Salt Solution (HBSS) (HyClone, HBSS/Modified, no calcium, 
magnesium) 
• Collagenase (Sigma Life Science, Collagenase from Clostridium histolyticum, > 
125 CDU/mg solid, Lot # SLBL6040V) 
• 50 mL conical tubes 
• 1.5 mL Eppendorf tubes 
• 100 µm cell strainers (Falcon Cell Strainers, Fisher Scientific 
 
Procedure: 
 
1. The day of the dissection, prepare a stock of 4 mg/mL collagenase/HBSS 
solution—keep on ice. 
2. Dissect and weigh adipose tissue depots and place in 10 mL cold HBSS. 
3. Pour tissue into petri dish (avoiding pouring out too much solution with it) and cut 
into small pieces with dissection scissors before putting into 15 mL tubes 
containing HBSS & collagenase (3 mL/1.2 g adipose tissue). 
4. Wrap with parafilm and place in incubator set at 37 ºC at 150 rpm. Incubate for 
20-30 min, and remove immediately when no visible tissue pieces remain. Place 
on ice to stop reaction. 
5. Skim floating adipocytes using plastic pipette, place in Eppendorf tubes on ice to 
allow for further separation. 
6. Filter remaining SVF portion through 100 µm strainers into 50 mL conical tubes. 
7. Use 200 µL pipet to remove SVF solution separated from adipocytes on ice. Filter 
this SVF through the 100 µm filter into the 50 mL tubes. 
8. Spin 50 mL tubes containing SVF for 10 minutes at 4 C, 260 rcf. 
9. While SVF is in centrifuge, add 1 mL Trizol to adipocytes in Eppendorf tubes. 
10. Remove SVF tubes from centrifuge, pour off supernatant, and tap to resuspend 
cells. Using 1000 µL pipet, transfer to Eppendorf tubes. Add 1 mL of Trizol to the 
50 mL conical tubes, pipet up and down to collect any cells remaining in tube, 
then transfer this to the Eppendorf tubes and freeze at -80ºC. 
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APPENDIX B: RNA ISOLATION 
Protocol adapted from (Lubbers 2012) 
Note: This protocol describes RNA isolation from both whole adipose tissue and 
adipocytes. It is noted where the two procedures differ. 
 
Materials: 
• Cells frozen in Trizol or whole adipose tissue frozen at -80ºC 
• Trizol reagent (Thermo Fisher Scientific, Life Technologies) (at 4ºC) 
• Chloroform (at RT) 
• Isopropyl alcohol (at RT) 
• Ice cold ethanol (at -20ºC) 
• Molecular grade water (at RT) 
• Syringes and needles 
• RNAse/DNAse-free pipette tips 
• Eppendorf tubes (RNAse/DNAse-free) 
• RNAse Away Decontamination Reagent (Thermo Fisher Scientific, Life 
Technologies) 
To prevent degradation of RNA by RNAses, thoroughly clean work area and all tools 
(including gloves, homogenizer tips, pipettes, and reagent tubes) with RNAse Away. 
 
Procedure: 
1. Add a 100-150 mg piece of frozen adipose tissue to Eppendorf tubes containing 
200 µL Trizol reagent. Be careful not to allow the tissue to thaw. 
2. Using a handheld homogenizer and homogenizer tips, homogenize adipose tissue 
in Trizol reagent until the contents are uniform. 
3. Add an additional 800 µL Trizol reagent to the Eppendorf tubes and briefly 
vortex. 
4. At this point, the procedures for isolating RNA from whole adipose tissue and 
adipose tissue cells become the same. After thawing the Eppendorf tubes 
containing adipose tissue cells and Trizol on ice, briefly vortex and centrifuge for 
5 min at 4ºC, 17xg (these settings will be maintained throughout the procedure).  
5. Following centrifugation, a lipid layer should float at the top of the Eppendorf 
tubes (NOTE: This is not present when isolating from stromal vascular cells). Use 
a syringe and needle to remove the pink, bottom layer, avoiding touching the 
floating lipid layer. 
6. Add 200 µL chloroform and vortex. Centrifuge again for 15 min. 
7. Using a 200 µL pipette, transfer the clear, top layer to a new, labelled tube, being 
careful not to touch the bottom Trizol layer. The Trizol in the first set of tubes 
may then be discarded appropriately. 
8. To the new set of tubes, add 500 µL isopropyl alcohol and vortex. Allow tubes to 
remain at room temperature for 5-10 min, then centrifuge for 10 min. During this 
centrifugation step, it is helpful to place all the tubes in the centrifuge in the same 
orientation, so it is easier to find the location of the RNA pellet. 
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9. At this point, an RNA pellet will have formed at the bottom of the Eppendorf 
tube. Pour out the supernatant, being careful not to disturb the RNA pellet. 
10. Add 1 mL ice-cold ethanol to the Eppendorf tubes and vortex. Centrifuge for 15 
min. Repeat this step two more times to clean the RNA pellet. 
11. After the final ethanol centrifugation, pour out the supernatant, tap gently on a 
paper towel sprayed with RNAse Away, and orient upside down, leaning against a 
pipette tip box so as to allow for airflow. Allow to dry for 1 hour. 
12. Suspend in 25 µL water by gently pipetting up and down. Freeze at -20ºC. 
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